Wyeth-Ayerst/Apollon enter into $100 mil. Genevax vaccines collaboration.
Executive Summary
WYETH-AYERST/APOLLON SIGN GENEVAX VACCINE COLLABORATION that could exceed $100 mil. if certain milestones are met, the companies announced Oct. 27. The agreement gives Wyeth-Ayerst exclusive worldwide marketing rights to Apollon's Genevax products for prevention and treatment of HIV, herpes simplex virus and human papilloma virus. Wyeth-Ayerst has the option to expand the agreement to include other indications.